Spain With a huge investment from AstraZeneca at its core, can the Spanish city of Barcelona really now rival more established European life sciences ecosystems? Back in 2023, Barcelona was a somewhat surprising choice for AstraZeneca’s new global R&D hub. The Catalan capital, Spain’s second largest city, lacks both the…
China Like most founders, my dream is to bring one of our own drugs to market and see patients genuinely benefit from our inventions Built on deep expertise in oligonucleotide chemistry, Leaderna Therapeutics is advancing a new generation of siRNA medicines for chronic diseases, with programmes spanning hypertension, dyslipidaemia and obesity.…
China Strong efficacy data attracts collaborators, but confidence shaken by other companies’ weaker results holds the whole field back Regend Therapeutics was founded in 2015 by Dr Ting Zhang and her husband, Professor Wei Zuo, to move stem cell research out of the lab and into patients. The company went on…
Germany Germany is one of Takeda’s largest markets, a major manufacturing base and an important clinical research location, yet its long-standing reputation for rapid access to innovation is coming under pressure. GM Germany Dr Ingeborg Borgheim discusses how Takeda is preparing its German operations for a new generation of launches, where…
China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Asieris’ $250M deal with Theramex for APL-1702 (CEVIRA®), MicuRx’s $974M collaboration with ClearideBio for MRX-23 and ADC programs, and Defand’s partnership with Roche on molecular glue degraders. Other updates feature DualityBio’s IPO progress, Akeso’s Phase III NSCLC trial, and…
India Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the country now has a narrow window to build the clinical-development capabilities needed to originate and test novel therapies itself. India…
APAC The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather than incremental process tweaks. That growth is already visible on the ground in APAC: AI has moved well beyond the…
Korea Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two decades, with Korea ranking among the world’s leading trial destinations as far back as 2018; years before China’s biotech ambitions…
Japan Japan is resetting itself as a clinical trial destination. Costs have halved, local data requirements are being relaxed, and the country is actively courting the global biotechs that have long overlooked it for trials. The opportunity is real; but so is the ground Japan still must make up. Japan’s…
Taiwan Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors – which have forced the island to adopt the most rigorous international standards and build a dense web of global…
China China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the global drug development pipeline. The high speed and low cost of Chinese trials are unmatched globally. However, in a volatile…
Korea We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum for the affiliate, driven by its fertility and oncology portfolios, as well as an improved access framework for innovative treatments…
See our Cookie Privacy Policy Here
